Jump to content

COX-inhibiting nitric oxide donator: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Fix Redirect to Ester#Ester_reactions
Line 1: Line 1:
'''COX-inhibiting nitric oxide donators''' ('''CINODs'''), also known as '''NO-NSAIDs''', are a new class of [[non-steroidal anti-inflammatory drug]] (NSAID) developed with the intention of providing greater safety than existing NSAIDs.
'''COX-inhibiting nitric oxide donators''' ('''CINODs'''), also known as '''NO-NSAIDs''', are a new class of [[non-steroidal anti-inflammatory drug]] (NSAID) developed with the intention of providing greater safety than existing NSAIDs.


These compounds were first described by John Wallace <ref>[http://www.ucalgary.ca/irn/wallace.htm John Wallace, Professor, Department of Pharmacology and Therapeutics, University of Calgary]</ref> and colleagues. CINODs are [[compound]]s generated by the fusion of an existing NSAID with a [[nitric oxide]] (NO)-donating [[functional group|moiety]] by chemical means, usually by [[ester#ester reactions|ester linkage]]. CINODs retain the [[anti-inflammatory]] efficacy of NSAIDs ''via'' inhibition of [[cyclooxygenase]] (COX) while arguably improving upon gastric and vascular safety, most likely ''via'' [[vasorelaxation]], inhibition of [[leukocyte]] [[cell adhesion|adhesion]] and inhibition of [[caspases]], all known effects of NO.
These compounds were first described by John Wallace <ref>[http://www.ucalgary.ca/irn/wallace.htm John Wallace, Professor, Department of Pharmacology and Therapeutics, University of Calgary]</ref> and colleagues. CINODs are [[compound]]s generated by the fusion of an existing NSAID with a [[nitric oxide]] (NO)-donating [[functional group|moiety]] by chemical means, usually by [[Ester#Ester_reactions|ester linkage]]. CINODs retain the [[anti-inflammatory]] efficacy of NSAIDs ''via'' inhibition of [[cyclooxygenase]] (COX) while arguably improving upon gastric and vascular safety, most likely ''via'' [[vasorelaxation]], inhibition of [[leukocyte]] [[cell adhesion|adhesion]] and inhibition of [[caspases]], all known effects of NO.


The first CINODs were developed in the 1990s, and as yet none have been approved for use by the general public. The importance of developing such drugs was increased when [[COX-2 inhibitor|COX-2-specific NSAIDs]] [[rofecoxib]] (Vioxx) and [[lumiracoxib]] (Prexige) were removed from major pharmaceutical markets in the mid-2000s due to [[COX-2 inhibitor#Risks and adverse effects|vascular safety concerns]]. In addition, traditional NSAIDs increase [[blood pressure]] and interfere with the actions of [[antihypertensive]] drugs. Several CINODs are currently being tested in [[clinical trials]], the most advanced of which are being conducted by the [[France|French]] [[pharmaceutical company]] [[NicOx]], whose flagship compound [[naproxcinod]] is in [[clinical trials#phase III|phase III trials]] for the treatment of [[osteoarthritis]].<ref>[http://www.drugdevelopment-technology.com/projects/azd3582/ HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation]</ref> Naproxcinod, also known as HCT 3012, AZD3582, NO-naproxen and nitronaproxen, is a fusion of [[naproxen]] and a NO-donating group. Other CINODs are also being tested by NicOx for the treatment of diseases in which inflammation plays a role.<ref>[http://www.nicox.com/update/portfolio.html NicOx pipeline: product portfolio]</ref>
The first CINODs were developed in the 1990s, and as yet none have been approved for use by the general public. The importance of developing such drugs was increased when [[COX-2 inhibitor|COX-2-specific NSAIDs]] [[rofecoxib]] (Vioxx) and [[lumiracoxib]] (Prexige) were removed from major pharmaceutical markets in the mid-2000s due to [[COX-2 inhibitor#Risks and adverse effects|vascular safety concerns]]. In addition, traditional NSAIDs increase [[blood pressure]] and interfere with the actions of [[antihypertensive]] drugs. Several CINODs are currently being tested in [[clinical trials]], the most advanced of which are being conducted by the [[France|French]] [[pharmaceutical company]] [[NicOx]], whose flagship compound [[naproxcinod]] is in [[clinical trials#phase III|phase III trials]] for the treatment of [[osteoarthritis]].<ref>[http://www.drugdevelopment-technology.com/projects/azd3582/ HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation]</ref> Naproxcinod, also known as HCT 3012, AZD3582, NO-naproxen and nitronaproxen, is a fusion of [[naproxen]] and a NO-donating group. Other CINODs are also being tested by NicOx for the treatment of diseases in which inflammation plays a role.<ref>[http://www.nicox.com/update/portfolio.html NicOx pipeline: product portfolio]</ref>

Revision as of 10:35, 3 October 2008

COX-inhibiting nitric oxide donators (CINODs), also known as NO-NSAIDs, are a new class of non-steroidal anti-inflammatory drug (NSAID) developed with the intention of providing greater safety than existing NSAIDs.

These compounds were first described by John Wallace [1] and colleagues. CINODs are compounds generated by the fusion of an existing NSAID with a nitric oxide (NO)-donating moiety by chemical means, usually by ester linkage. CINODs retain the anti-inflammatory efficacy of NSAIDs via inhibition of cyclooxygenase (COX) while arguably improving upon gastric and vascular safety, most likely via vasorelaxation, inhibition of leukocyte adhesion and inhibition of caspases, all known effects of NO.

The first CINODs were developed in the 1990s, and as yet none have been approved for use by the general public. The importance of developing such drugs was increased when COX-2-specific NSAIDs rofecoxib (Vioxx) and lumiracoxib (Prexige) were removed from major pharmaceutical markets in the mid-2000s due to vascular safety concerns. In addition, traditional NSAIDs increase blood pressure and interfere with the actions of antihypertensive drugs. Several CINODs are currently being tested in clinical trials, the most advanced of which are being conducted by the French pharmaceutical company NicOx, whose flagship compound naproxcinod is in phase III trials for the treatment of osteoarthritis.[2] Naproxcinod, also known as HCT 3012, AZD3582, NO-naproxen and nitronaproxen, is a fusion of naproxen and a NO-donating group. Other CINODs are also being tested by NicOx for the treatment of diseases in which inflammation plays a role.[3]

References

  1. ^ John Wallace, Professor, Department of Pharmacology and Therapeutics, University of Calgary
  2. ^ HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation
  3. ^ NicOx pipeline: product portfolio
  • Wallace JL, Reuter BK, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 172-179. PMID 8020659
  • Wallace JL, Cirino G. The development of gastrointestinal-sparing anti-inflammatory drugs. Trends Pharmacol Sci 1994; 15: 405-406. PMID 7855901
  • Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002;137:295-310. PMID 12237248
  • White, WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49(3):408-18. PMID: 17261646[1]


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=COX-inhibiting_nitric_oxide_donator&oldid=242717929"